RET and thyroid gland carcinoma: Few data in the second line, and the advent of drugs with recent FDA approval (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions accessed on 8 January 2021) (https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions accessed on 8 January 2021), relegate platinum based plus pemetrexed combination in subsequent lines, and in any case, after selective targeted therapies and available new drugs in clinical trials [86].